Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease

The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is poor, and 5%‐20% of those receiving chemotherapy experience ILD exacerbation. To evaluate the safety and efficacy of nab‐paclitaxel plus carboplatin for NSCLC patients with ILD, we undertook a multic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenmotsu, Hirotsugu, Yoh, Kiyotaka, Mori, Keita, Ono, Akira, Baba, Tomohisa, Fujiwara, Yutaka, Yamaguchi, Ou, Ko, Ryo, Okamoto, Hiroaki, Yamamoto, Nobuyuki, Ninomiya, Takashi, Ogura, Takashi, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890441/
https://www.ncbi.nlm.nih.gov/pubmed/31608537
http://dx.doi.org/10.1111/cas.14217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890441/
https://www.ncbi.nlm.nih.gov/pubmed/31608537
http://dx.doi.org/10.1111/cas.14217

Ejemplares similares